|
Richard A. Flavell, Ph.D., is Chairman and Sterling Professor of Immunobiology at Yale University School of Medicine and a Howard Hughes Medical Institute Investigator. Prior to his current position at Yale University, Dr. Flavell was President and Chief Scientific Officer of Biogen, Inc. from 1982 to 1988. He has served as a scientific advisor for numerous biotechnology companies since 1980 including Celltech, CuraGen and Biogen, and is a member of the Cancer Research United Kingdom Scientific Committee. He is an author of over 500 scientific publications, editor of numerous scientific journals, a fellow of the Royal Society, and a member of the National Academy of Sciences and several other distinguished societies. Dr. Flavell received his Ph.D. in biochemistry from the University of Hull in Great Britain, with subsequent post-doctoral study at the University of Amsterdam and the University of Zurich. | 